Ginkgo Bioworks is expected to report Q3 2026 revenue of $48.5 million and an EPS loss of $0.58, with the current stock price of $7.25 trading significantly below the average analyst target of $12.50. The primary focus for investors is the year-over-year growth in Cell Engineering revenue as the company completes its transition away from legacy biosecurity contracts.
Management is under pressure to demonstrate that its 2024 restructuring plan has effectively reduced operational cash burn and improved gross margins. Analysts are specifically looking for evidence that the modular Ginkgo Lab Services model is successfully attracting high-value biotech and pharmaceutical partners.